CombiGene AB (publ) announced that Annika Ericsson, current Director Preclinical Development, will take over the role of Chief Scientific Officer, after Karin Agerman, who has decided to leave the company. Annika has worked almost as long as Karin in the company and has solid experience in drug development of gene therapies in the preclinical phase and project management. She started by running the preclinical testing of CG01 and has subsequently been project manager in several projects, most recently for CGT2, the lipodystrophy project, and COZY02, CombiGene's latest gene therapy project that targets severe chronic pain where there is currently a lack of good treatment options.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 SEK | 0.00% |
|
-2.58% | +12.27% |
24/06 | CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01 | CI |
27/05 | CombiGene Appoints New Chief Scientific Officer | MT |
1st Jan change | Capi. | |
---|---|---|
+12.27% | 5.66M | |
+16.49% | 122B | |
+21.73% | 115B | |
+22.33% | 26.64B | |
-21.81% | 19.91B | |
-16.71% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- COMBI Stock
- News CombiGene AB
- Combigene AB Appoints Annika Ericsson as New Chief Scientific Officer